Galena Biopharma, Inc. Email Format
Biotechnology ResearchCalifornia, United States51-200 Employees
Galena Biopharma, Inc. is a biotechnology research company focused on developing and commercializing targeted oncology therapies. Its work spans mid- to late-stage clinical assets, with an emphasis on immunotherapy programs such as NeuVax™ (nelipepimut-S), currently in international Phase 3 testing, alongside commercial drugs like Abstral® (fentanyl) sublingual tablets and Zuplenz® (ondansetron) oral soluble film. The company aims to address cancer care across its spectrum by advancing treatments that target the disease while mitigating associated side effects. Based in San Ramon, California, the firm operates in the biotechnology research sector and serves healthcare providers and patients within oncology. As a public company listed on NASDAQ, Galena’s activities include pursuing clinical development and commercialization opportunities within its oncology portfolio. A recent development noted is the public reporting of a class-action securities lawsuit filed against the company in February 2017.